A Single Dose of Neoadjuvant PD-1 Blockade Predicts Clinical Outcomes in Resectable Melanoma

Immunologic responses to anti-PD-1 therapy in melanoma patients occur rapidly with pharmacodynamic T cell responses detectable in blood by 3 weeks. It is unclear, however, whether these early blood-based observations translate to the tumor microenvironment. We conducted a study of neoadjuvant/adjuva...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Alexander C., Orlowski, Robert J., Xu, Xiaowei, Mick, Rosemarie, George, Sangeeth M., Yan, Patrick K., Manne, Sasikanth, Kraya, Adam A., Wubbenhorst, Bradley, Dorfman, Liza, D’Andrea, Kurt, Wenz, Brandon M., Liu, Shujing, Chilukuri, Lakshmi, Kozlov, Andrew, Carberry, Mary, Giles, Lydia, Kier, Melanie W., Quagliarello, Felix, McGettigan, Suzanne, Kreider, Kristin, Annamalai, Lakshmanan, Zhao, Qing, Mogg, Robin, Xu, Wei, Blumenschein, Wendy M., Yearley, Jennifer H., Linette, Gerald P., Amaravadi, Ravi K., Schuchter, Lynn M., Herati, Ramin S., Bengsch, Bertram, Nathanson, Katherine L., Farwell, Michael D., Karakousis, Giorgos C., John Wherry, E., Mitchell, Tara C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6699626/
https://www.ncbi.nlm.nih.gov/pubmed/30804515
http://dx.doi.org/10.1038/s41591-019-0357-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6699626/
https://www.ncbi.nlm.nih.gov/pubmed/30804515
http://dx.doi.org/10.1038/s41591-019-0357-y

Ejemplares similares